Jackie Syrop

Nevada Governor Brian Sandoval is supportive of bipartisan bill SB 539 after it hones in on both, the pharmaceutical companies and pharmacy benefit managers (PBMs).

Nevada bill SB 265, which would have required pharmaceutical companies that make diabetes drugs to disclose information on insulin pricing, profits, and costs, and to publicly post that information, was vetoed by Nevada Governor Brian Sandoval. Sandovol cited concerns over “nascent, unproven, and disruptive” changes to state healthcare policy.

The potential cost savings offered by biosimilars may never be realized in the United States if reimbursement incentives are not implemented to ensure their adoption and long-term use, according to industry expert Molly Burich.